Quarterly Report 2, April 2016

Dear Shareholders

The second quarter of this fiscal year and the period thereafter have been exciting and eventful. We presented preliminary reports from three different ongoing combination studies with the diabetes vaccine Diamyd®: 1) DIABGAD (Diamyd®/ibuprofen/vitamin D); 2) DIAGNODE (intralymphatic injection of Diamyd®/vitamin D); 3) EDCR (Diamyd®/etanercept/vitamin D), and all have shown a good safety profile thus far. We applied for and, after the end of the period, received approval from both the Swedish Medical Products Agency and the Ethics Review Board for a certain extension of the DIAGNODE trial, and we are engaged in discussions regarding an extension of the GABA/Diamyd® trial in Birmingham/Alabama. An agreement was...

We aim to cure type 1 diabetes by first inducing immunological tolerance to the insulin-producing beta cells and then restore the functional beta cell mass by stem cell therapy.
Anders Essen-Möller, President and CEO

Annual Report

  November 05, 2015
 

A DEDICATED DIABETES COMPANY

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

The Share

The Diamyd Medical share is traded on NASDAQ Stockholm First North (ticker : DMYD B).

About First North

First North is an alternative marketplace operated by an exchange within the NASDAQ OMX group. Companies on First North are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on First North may therefore be higher than investing in a company on the main market. All companies with shares traded on First North have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at First North

Remium Nordic AB, Kungsgatan 12-14, 111 35 Stockholm, 08-454 32 00, www.remium.com

Calendar

Dates for financial information and other events
 June 29, 2016
Quarterly Report III
 October 12, 2016
Financial Statement

Holdings

NamePositionA SharesB Shares
Anders Essen-Möller Board Member 1 278 112 3 668 089
Maria-Teresa Essen-Möller Board Member 32 000
Erik Nerpin Chairman of the Board 20 533
Fredrik Åhlander Board Member
Ulf Hannelius CEO 20 000
Anna Styrud Chief Financial Officer 40 000
Erika Hillborg Senior Director Clinical Development 8 000
Bertil Lindkvist Major Holder 3 815 040
Johan Pharmanson Principal Auditor, BDO

Transaction history

NameChangeTypeDate
Data pager
Data pager
123
Show:
PageSizeComboBox
select
3 pages
Ulf Hannelius + 20 000 B Share 2016-04-27
Bertil Lindkvist + 1 057 185 BTA B to B shares 2016-03-21
Erika Hillborg + 2 000 BTA B to B shares 2016-03-21
Anna Styrud + 10 000 BTA B to B shares 2016-03-21
Erik Nerpin + 5 133 BTA B to B shares 2016-03-21
Maria-Teresa Essen-Möller + 8 000 BTA B to B shares 2016-03-21
Anders Essen-Möller + 13 658 BTA B to B shares 2016-03-21
Anders Essen-Möller + 319 528 BTA A to A shares 2016-03-21
Bertil Lindkvist + 60 000 BTA B 2016-03-02
Anders Essen-Möller + 319 528 Subscr. rights A to BTA A 2016-02-22

Ten largest shareholders as of March 31, 2016

ShareholderA SharesB SharesShare Capital (%)Votes (%)
Essen-Möller, Anders 1 278 112 3 666 521 16.77 40.12
Avanza Pension 4 091 351 13.87 9.98
Lindkvist, Bertil 3 815 040 12.94 9.31
Nordnet Pensionsförsäkring AB 902 482 3.06 2.2
Robur Försäkring 578 810 1.96 1.41
Protein Sciences Corporation 400 000 1.36 0.98
Waldolf, Rolf Eric 298 666 1.01 0.73
Försäkrings AB Skandia 291 644 0.99 0.71
Handelsbanken Liv 263 097 0.89 0.64
Bohlin, Lennart 249 998 0.85 0.61
Remaining shareholders 13 656 841 46.30 33.31
Total 1 278 112 28 214 450 100.00 100.00